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background:  We previously compared cardiovascular (CV) events between patients achieving a LDL particle (LDL-P) target vs. LDL 
cholesterol (LDL-C) target in high risk patients from a large commercially insured US population. This study extends these analyses by 
including lower-risk primary prevention patients.
Methods:  Adult patients were selected from the HealthCore Integrated Research DatabaseSM. Patients who achieved LDL-P <1000 
nmol/L between 2006 and 2012 were placed into the LDL-P cohort with index date as the earliest observed LDL-P target. Patients without 
LDL-P tests, but who achieved LDL-C <100 mg/dL, were placed into the LDL-C cohort. Baseline characteristics were assessed 6 months 
pre-index. Patients were followed for 12-36 months post-index. Pre-index demographic and comorbidity differences were balanced 
between cohorts using propensity score matching while treatment patterns were left intact.
Results:  LDL-P patients were more likely to receive higher potency statins and more non-statin lipid lowering drugs at baseline. During 12-
36 months follow-up, LDL-P patients had fewer CV events vs. LDL-C patients (36 month HR= 0.77; 95% CI 0.62-0.97; NNT=30).
conclusion:  Results in this extended sample including both primary and secondary prevention patients are consistent with previous 
results in a higher-risk-only sample. More aggressive lipid-lowering treatment in patients achieving LDL-P <1000 is associated with a 
reduction in CV event rates over 12-36 months follow-up.
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Baseline Characteristics
Age, mean (SD) 57.0 (10) 56.3 (10.3) 0.007 57.0 (9.9) 56.5 (10.8) 0.168 57.0 (9.7) 56.2 (10.2) 0.081
Female, n (%) 1267 (43.1) 1296 (44.1) 0.446 723 (41.9) 742 (43) 0.513 405 (41.7) 400 (41.2) 0.818
Primary CVD risk status*, n (%) 848 (28.8) 840 (28.6) 0.818 482 (28) 446 (25.9) 0.167 266 (27.4) 264 (27.2) 0.919
Secondary CVD risk status*, n (%) 2094 (71.2) 2102 (71.5) 0.818 1242 (72) 1278 (74.1) 0.167 705 (72.6) 707 (72.8) 0.919
Diabetes mellitus, n (%) 1183 (40.2) 1192 (40.5) 0.811 692 (40.1) 745 (43.2) 0.067 407 (41.9) 432 (44.5) 0.252
Cardiovascular disease, n (%) 1313 (44.6) 1304 (44.3) 0.813 778 (45.1) 783 (45.4) 0.864 425 (43.8) 399 (41.1) 0.233
QCI Comorbidity score, mean (SD) 0.82 (1.2) 0.89 (1.3) 0.045 0.82 (1.2) 0.94 (1.2) 0.002 0.83 (1.1) 0.9 (1.1) 0.174
Lipid-lowering medications, n (%) 
with ≥1 fill
2066 (70.2) 1934 (65.7) <.001 1227 (71.2) 1180 (68.5) 0.081 673 (69.3) 640 (65.9) 0.110
Statin potency level 3, n (%) 538 (18.3) 648 (22) <.001 320 (18.6) 413 (24) <.001 174 (17.9) 218 (22.5) 0.013
Statin potency level 4, n (%) 1080 (36.7) 891 (30.3) <.001 624 (36.2) 560 (32.5) 0.022 346 (35.6) 313 (32.2) 0.114
Statin potency level 5, n (%) 290 (9.9) 132 (4.5) <.001 166 (9.6) 92 (5.3) <.001 85 (8.8) 29 (3) <.001
Ezetimibe 202 (6.87) 130 (4.42) <.001 142 (8.24) 93 (5.39) <.001 96 (9.89) 57 (5.87) <.001
Niacin 251 (8.53) 79 (2.69) <.001 158 (9.16) 38 (2.2) <.001 83 (8.55) 25 (2.57) <.001
Prescription Omega 3 fatty acids 103 (3.5) 58 (1.97) <.001 54 (3.13) 20 (1.16) <.001 27 (2.78) 16 (1.65) 0.090
LDL-P, mean (SD) 863.1 (105.8) N/A N/A 867.5 (104) N/A N/A 868.2 (103.3) N/A
LDL-C, mean (SD) 73.9 (20.8) 79.8 (14.5) <.001 75.3 (21.4) 80.5 (14.2) 0.001 74.9 (22.1) 80.2 (14.5) <.001
HDL-C, mean (SD) 54.1 (15.4) 47.9 (13.7) <.001 52.8 (14.7) 47.8 (13.6) <.001 52.7 (14.8) 47.4 (13.3) <.001
Follow-up CV Event Risk†
≥1 event, n (%) 138 (4.7) 200 (6.8) <.001 148 (8.6) 183 (10.6) 0.043 114 (11.7) 146 (15.0) 0.033
Events, mean (SD) 0.08 (0.43) 0.11 (0.50) 0.006 0.15 (0.62) 0.21 (0.80) 0.018 0.22 (0.75) 0.32 (1.02) 0.014
Hazard Ratio (95% CI) 0.68 (0.55-0.85) <.001 0.80 (0.64-0.99) 0.041 0.77 (0.62-0.97) 0.035
Absolute Risk Reduction /Number 
Needed to Treat (NNT)
2.11% / 47 N/A 2.03% / 49 N/A 3.30% / 30 N/A
*) Primary CVD risk status was defined as occurrence of at least 2 of the following conditions at any time prior to index date: (1) Age - males >45 and females >55; (2) HDL-C - males <40 mg/dL and females <50 mg/dL; 
(3) At least 1 claim for hypertension and at least 1 fill for antihypertensive medications. Secondary CVD risk status was defined as occurrence of at least 1 of the following conditions at any time prior to index date: (1) 
established CHD, stroke, TIA, or peripheral arterial disease or a prescription fill for clopidogrel; (2) at least 2 claims for diabetes mellitus or at least 1 prescription fill for an antidiabetic medication.
†) Defined as CHD (myocardial infarction, angina, revascularization) and stroke events identified by ICD-9-CM diagnoses and procedural codes and Common Procedural Terminology codes on medical claims in an 
inpatient or emergency room setting.
